Therapeutic Effect of Sodium Selenite and Zinc Sulphate as Supplementary with Meglumine Antimoniate( Glucantime®) Against Cutaneous Leishmaniasis In BALB/C Mice
-
F Zamani Sorkhroodi
,
AM Alavi Naeini
,
AR Zahraei Ramazani
,
MR Aghaye Ghazvini
,
M Mohebali
,
SA Keshavarz
Abstract
Background: Successful therapy of leishmaniasis depends on effective cellular immune response. We evaluated the effectiveness of sodium selenite and zinc sulphate as known immunomodulator materials, in combination with Glucantime® in treatment of cutaneous leishmaniasis lesions resulting from Leishmania major in susceptible animal model.
Methods: Thirty three female mice weighing 18-20 g at the age of 7-8 week infected with L. major were randomly divided into 3 groups: group1: treated by sodium selenite (0.35 mg/kg for 30 days), group2: treated by zinc sulphate (2 mg/kg for 30 days) and group3: treated by distilled water (0.01 ml/gr body weight for 30 days) as control. All groups received Glucantime® as a standard anti- leishmanial agent (60 mg/kg, ip) for 14 days. To assess the results of treatment measurement of lesions size and parasitological tests were done weekly.
Results: The lesion sizes increased continuously in sodium selenite group .Although, in zinc group did not increase compared to baseline But with considering the time- group interaction there was no significant difference between zinc and control group during this study. There was no difference between lesion sizes and Leishmanial loads in the interventional and control groups, respectively.
Conclusion: Sodium selenite and zinc sulphate at mentioned doses and duration of treatment did not show any treatment effect on cutaneous leishmaniasis caused by L. major in BALB/c mice. Increasing the dose of supplements and considering the follow up period after treatment can help more certain conclusion.
World Health Organization (WHO), 1990. The leishmaniasis. Technical report, pp.793, 27.
World Health Organization (WHO), 2000. Leishmaniasis and Leishmania/HIV co infection, WHO/CDC/CSR/ISR, pp.1-2.
Tuon FF, Amato VS, Graf ME, Siqueira AM, Nicodemo AC, Amato Neto V. Treatment of New World cutaneous leishmaniasis--a systematic review with a meta-analysis. Int J Dermatol. 2008 Feb; 47(2):109-24.
Von Stebut E. Immunology of cutaneous leishmaniasis: the role of mast cells, phagocytes and dendritic cells for protective immunity. Eur J Dermatol. 2007; 17(2):115-22.
Murray HW, Nathan CF. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med. 1999; 189(4):741-746.
Kharazmi A, Kemp K, Ismail A, Gasim S, Gaafar A, Kurtzhals JA, El Hassan AM,m Theander TG, Kemp M. T-cell response in human leishmaniasis. Immunol Lett. 1999; 65(1-2):105-8.
Li J, Sutterwala S, Farrell J.P. Successfultherapy of chronic, nonhealing murine cutaneous leishmaniasis with sodium stibogluconate and gamma interferon depends on continued interleukin-12 production.” Infection and immunity, 1997; 65(8):3225-3230.
Sprietsma JE. Zinc-controlled Th1/Th2 switch significantly determines development of diseases. Med Hypothesis. 1997; 49(1):1-14.
Mahan LK, Escott-Stump S (eds). Krause’s Food and Nutrition therapy. 2008; 11th ed, WB Saunders Co, Philadelphia; pp: 39-135.
Van Weyenbergh J, Santana G, D'Oliveira A Jr, Santos AF Jr, Costa CH, Carvalho EM, Barral A, Barral-Netto M. Zinc/copper imbalance reflects immune dysfunction in human leishmaniasis: an ex vivo and in vitro study. BMC Infect Dis. 2004;17,4:50.
Yazdan Panah MJ, Mostoufi SK, Soleimani M. Oral Zinc Sulfate in the treatment of acute cutaneous Leishmaniasis. IR J Dermatol. 2003; 22(6): 24-20(In Persian).
Serarslan G, Ylmaz HR, Sugut S. Serum antioxidant activities, malondialdehyde and nitric oxide levels in human cutaneous leishmaniasis. Clin Exp Dermatol. 2005; 30(3):267-71.
Vural H, Aksoy N and Ozbilge H. Alteration of oxidative-antioxidative status in cutaneous leishmaniasis. Cell Biochem Funct.2004; 22(3):153-156.
Bildik A, Kargin F, Seyrek K, Pasa S, Ozensoy S. Oxidative stress and nonenzymatic antioxidative status in dogs with visceral leishmaniasis. Res Vet Sci. 2004; 77(1):63-6.
Hoffmann PR, Berry MJ. The influence of selenium on immune responses. Mol Nutr Food Res. 2008: 52(11):1273-80.
Mukhopadhyay R, Madhubala R. Effect of antioxidants on the growth and polyamine levels of Leishmania donovani. Biochem Pharmacol. 1994; 74(4):611-5.
Kocyigit A, Erel O, Gurel M.S , Seyrek A, Aktepe N, Avcı Ş . Decreasing selenium levels and glutathione peroxidase activity in patients with cutaneous leishmaniasis. Tr J of Medical Sciences. 1999; 29: 291-295.
Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K,Engel J, Sindermann H. Miltefosine for new world bcutaneous leishmaniasis. Clin Infect Dis. 2004, 1; 38(9):1266-1272.
Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, Razaghian A.R, Kabir M.J , Nadim A. Comparison of miltefosine and meglumine antimoniate (GlucantimeR) for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Tropica. 2007;103(1):33-40.
Rossi-Bergmann B, Müller I, Godinho EB. TH1 and TH2 T-cell subsets are differentially activated by macrophages and B cells in murine leishmaniasis. Infect Immun. 1993; 61(5):2266-9.
Ozonlins TR, Sikasay DL, Wells PG. Modulation of embryonic glutathion peroxidase activity and phenytoin teratogenicity by dietary deprivation of selenium in CD-1 mice . J Pharmacol Exp Ther. 1996; 277 (2): 945-53.
World Health Organization. Basic laboratory methods in medical parasitology 1991; Section1.pp:58-61.
Bisti S, Konidou G, Boelaert J et al. The prevention of growth of Leishmania major progeny in Balb/c iron-loaded mice: a process coupled to increased oxidative burst, the amplitude and duration of which depend on initial parasite developmental stage and dose.” Microbes and infection. 2006; 8(6):1464-72.
Iraji F, Vali A, Asiliyan A, Shah Talebi MA. Comparison of intralesionally injected Zinc Sulfate and Pentavalent Antimony compound in treatment of acute cutaneous Leishmaniasis. J Kerman University Med Sci 2000; 4(7): 166-161.
Sharquie KE, Najim RA, Farjou IB. A comparative controlled trial of intralesionally- administerd zinc sulfate, hypertonic chloride and pentavalent antimony compound against acute cutaneous leishmaniasis. Clin Exp Dermatol. 1997; 22(4):169-73.
Firooz AR, Khatami AR, Khamesipour A, Nassiri Kashani M, Nilforoushzadeh MA, Behnia F, Pazoki Toroudi HR, Dowlati Y. A comparison between the efficacy of intralesional injection of 2% Zinc Sulfate solution with Glucantime® in the treatment of acute old world cutaneous Leishmaniasis: A randomized, double-blind, controlled clinical trial. IR J Dermatol 2004; 28(7): 218-209.
Najim RA, Sharquie KE, Faarjou IB. Zinc sulfate in the treatment of cutaneous leishmaniasis: an in vitro and animal study. Mem Inst Oswaldo Cruz, Rio de Janeiro. 1998; 93(6):831-837.
Sharquie KE, Najim RA, Farjou IB, Al- Timmy DJ .Oral zinc sulfate in the treatment of acute cutaneous leishmaniasis. Clin Exp Dermatol. 2001; 26(1):21-6.
Obminiska-Domoradzka B, Szczypka M, Debowy J. Effects thymomimetic drugs and zinc supplementation on the cellular immune response in hydrocortisone-suppressed mice. J Vet Med B Infect Dis Vet Public Health. 2002; 49(10):469-75.
Banu BS, Devi KD, Mahboob M, Jamil K. In vivo genotoxic effect of zinc sulfate in mouse peripheral blood leukocytes using Comet assay. Drug Chem Toxicol. 2001; 24(1):63-73.
Pourfallah F, Javadian S, Zamani Z, Saghiri R, Sadeghi S, Zarea B, Faiaz Sh,Mirkhani F, Fatemi N. Evaluation of serum levels of zinc, copper, iron, and zinc/copper ratio in cutaneous leishmaniasis. Iranian J Arthropod-Borne Dis. 2009; 3(2): 7-11.
Faryadi M, Mohebali M. Alterations of serum zinc, copper, and iron concentrations in patients with acute and chronic cutaneous leishmaniasis. Iranian J Publ Health, 2003; 32(4):53-58.
| Files | ||
| Issue | Vol 5 No 3 (2010) | |
| Section | Articles | |
| Keywords | ||
| Leishmania major Sodium selenite Zinc sulphate Meglumine Antimoniate (glucantime®) BALB/c | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
